Literature DB >> 19513605

Targeting and internalization of sterically stabilized liposome modified with ZCH-4-2E8.

Jingying Zhang1, Yongmin Tang, Hongqiang Shen, Baiqin Qian.   

Abstract

Sterically stabilized liposome (SL) modified with 2E8 monoclonal antibody (2E8-SL) was prepared in order to evaluate its targeting ability and internalization efficiency against tumor cells with high expression of CD19. 2E8 was coupled to the surface of SL using post-insertion technique. The shape of liposomes was observed under a transmission electronic microscope. The average size of liposomes was determined by using the Zetasizer instrument. The binding and internalization of 2E8-SL against tumor cells with higher expression of CD19 were tested by flow cytometry and confocal microscopy. The mean diameter of 2E8-SL was 121.25 nm. 2E8-SL was stable after up to 24 days in various buffers. 2E8-SL showed specific binding to tumor cells with high expression of CD19, including B cells in peripheral blood mononuclear cells (PBMCs). 2E8-SL could efficiently internalize into Nalm6 cells with CD19 high expression. It is suggested that 2E8-SL may serve as useful delivery carrier of anti-cancer drugs targeting to hematological malignant tumors with CD19 high expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513605     DOI: 10.1007/s11596-009-0302-2

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  25 in total

Review 1.  Ligand-targeted liposomes for cancer treatment.

Authors:  Puja Sapra; Pradeep Tyagi; Theresa M Allen
Journal:  Curr Drug Deliv       Date:  2005-10       Impact factor: 2.565

2.  In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach.

Authors:  D L Iden; T M Allen
Journal:  Biochim Biophys Acta       Date:  2001-08-06

3.  Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

Authors:  Herbert I Hurwitz; Louis Fehrenbacher; John D Hainsworth; William Heim; Jordan Berlin; Eric Holmgren; Julie Hambleton; William F Novotny; Fairooz Kabbinavar
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

4.  Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels.

Authors:  Tomohiro Asai; Kosuke Shimizu; Masami Kondo; Koichi Kuromi; Koh Watanabe; Koichi Ogino; Takao Taki; Satoshi Shuto; Akira Matsuda; Naoto Oku
Journal:  FEBS Lett       Date:  2002-06-05       Impact factor: 4.124

5.  Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.

Authors:  Puja Sapra; Theresa M Allen
Journal:  Clin Cancer Res       Date:  2004-04-01       Impact factor: 12.531

6.  In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

Authors:  D E Lopes de Menezes; L M Pilarski; T M Allen
Journal:  Cancer Res       Date:  1998-08-01       Impact factor: 12.701

7.  Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments.

Authors:  Puja Sapra; Elaine H Moase; Jie Ma; Theresa M Allen
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

8.  CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells.

Authors:  Masamitsu Harata; Yasushi Soda; Kenzaburo Tani; Jun Ooi; Tomoko Takizawa; Minghan Chen; Yuansong Bai; Kiyoko Izawa; Seiichiro Kobayashi; Akira Tomonari; Fumitaka Nagamura; Satoshi Takahashi; Kaoru Uchimaru; Tohru Iseki; Takashi Tsuji; Tsuneo A Takahashi; Kanji Sugita; Shinpei Nakazawa; Arinobu Tojo; Kazuo Maruyama; Shigetaka Asano
Journal:  Blood       Date:  2004-05-20       Impact factor: 22.113

9.  Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.

Authors:  F M Uckun; W Jaszcz; J L Ambrus; A S Fauci; K Gajl-Peczalska; C W Song; M R Wick; D E Myers; K Waddick; J A Ledbetter
Journal:  Blood       Date:  1988-01       Impact factor: 22.113

10.  In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.

Authors:  Alberto Gabizon; Aviva T Horowitz; Dorit Goren; Dina Tzemach; Hilary Shmeeda; Samuel Zalipsky
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

View more
  3 in total

1.  Preparation and evaluation of norcantharidin-encapsulated liposomes modified with a novel CD19 monoclonal antibody 2E8.

Authors:  Jingying Zhang; Yongmin Tang; Baiqin Qian; Hongqiang Sheng
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-04-21

2.  Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

Authors:  Diying Shen; Yongmin Tang; Sisi Li; Weiqun Xu; Lingyan Zhang
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-08

3.  CD19-antigen specific nanoscale liposomal formulation of a SYK P-site inhibitor causes apoptotic destruction of human B-precursor leukemia cells.

Authors:  Dorothea E Myers; Seang Yiv; Sanjive Qazi; Hong Ma; Ingrid Cely; Anoush Shahidzadeh; Martha Arellano; Erin Finestone; Paul S Gaynon; Amanda Termuhlen; Jianjun Cheng; Fatih M Uckun
Journal:  Integr Biol (Camb)       Date:  2014-08       Impact factor: 2.192

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.